| Literature DB >> 31929801 |
Kovvuru Praneeth Kumar Reddy1, Kale Muni Sai Prathap1, Hemraj Sharma1,2, Kondareddy Vinod Kumar1.
Abstract
An analytical method has been developed based on a colorimetric assay for the estimation of raloxifene hydrochloride, followed by validation of the optimized method by using the ICH guidelines. The new method, aromatic ring derivatization technique, is based on a coupling reaction using modified Romini's reagent in which sodium nitroprusside is used as a chromogenic derivatizing reagent. Raloxifene contains a phenolic hydroxyl group, containing reactive hydrogen. This reactive proton reacts with sodium nitroprusside and reduces it to sodium meta-hydrogen ferrocyano nitrate, which is a colored product. Optimization studies revealed that the coupling reaction was very rapid and completed in less than 1 minute. A 1 : 1 drug-to-reagent stoichiometric ratio was obtained for the azo dye formed. The azo adduct formed exhibits a bathochromic shift with absorption maximum λ max at 440 nm, which was selected as the analytical wavelength. The drug seems to be linear, which was established via the regression analysis from 20 to 120μg/ml. LOD and LOQ of the developed method were found to be 1.807μg/ml and 5.47μg/ml, respectively. Interday and intraday precision was studied, and %RSD was less than 2. Since the stability of the drug and the reagent was found to be predominantly massive, this method can be used for the formulation of raloxifene hydrochloride . The method can be extended for the routine assay of raloxifene formulations.Entities:
Year: 2019 PMID: 31929801 PMCID: PMC6935795 DOI: 10.1155/2019/3021980
Source DB: PubMed Journal: Int J Anal Chem ISSN: 1687-8760 Impact factor: 1.885
Figure 1Structure of raloxifene hydrochloride.
Figure 2Formation of the colored complex.
Figure 3Volume optimization of the modified sodium nitroprusside reagent at 5.5 ml.
Figure 4Volume optimization curve for 0.1% zinc chloride at 0.8 ml.
Stability of the colored complex of 120 μg·ml−1 with respect to time (hours).
| Time (hours) | Optical density |
|---|---|
| 4 | 0.20 |
| 8 | 0.21 |
| 12 | 0.21 |
| 16 | 0.21 |
| 20 | 0.21 |
| 24 | 0.21 |
| 28 | 0.21 |
| 32 | 0.21 |
| 36 | 0.21 |
| 40 | 0.21 |
| 44 | 0.20 |
| 48 | 0.18 |
Figure 5Calibration curve for raloxifene hydrochloride.
Intraday and interday precision.
| Concentration ( | Intraday ( | Interday ( | ||
|---|---|---|---|---|
| Amount of drug found (mean ± SD) | % RSD | Amount of drug found (mean ± SD) | % RSD | |
| 40 | 39.9 ± 0.115 | 0.288 | 39.16 ± 0.55 | 1.40 |
| 80 | 80.43 ± 0.763 | 0.948 | 78.16 ± 1.16 | 1.48 |
| 120 | 119.9 ± 0.173 | 0.144 | 119.3 ± 0.458 | 0.38 |
Accuracy of raloxifene hydrochloride.
| Name of the drug | Concentration of drug ( | Recovery level (%) | Amount of drug added ( | Amount found ( | % recovery ( |
|---|---|---|---|---|---|
| Raloxifene hydrochloride | 50 | 80 | 40 | 40.2 ± 0.057 | 100.5 |
| 100 | 50 | 49.8 ± 0.115 | 99.6 | ||
| 120 | 60 | 60.2 ± 0.121 | 100.33 |
n = number of replicates; SD = standard deviation.
LOD and LOQ value for raloxifene hydrochloride.
| Parameter | Raloxifene |
|---|---|
| LOD ( | 1.8074 |
| LOQ ( | 5.477 |
Assay for raloxifene hydrochloride.
| Formulationa | Labelled claim | Amount found (mean ± SD) | Assay (%) |
|---|---|---|---|
| Tablet 1 | 60 mg | 59.85 ± 0.105 | 99.75 |
| Tablet 2 | 60 mg | 59.69 ± 0.194 | 99.48 |
aTablet 1 and tablet 2 are two formulations from two different companies.